<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711421165</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711421165</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group><article-title>α-Lipoic Acid, Diabetic Neuropathy, and Nathan’s Prophecy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Papanas</surname>
<given-names>N.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711421165">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711421165"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maltezos</surname>
<given-names>E.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711421165">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711421165">
<label>1</label> Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, Greece</aff>
<author-notes>
<corresp id="corresp1-0003319711421165">N. Papanas, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece Email: <email>papanasnikos@yahoo.gr</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>81</fpage>
<lpage>83</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Both oral and intravenous administration of alpha-lipoic acid (ALA) has been investigated as add-on treatment for diabetic peripheral neuropathy. The recent Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial has shown that 4-year oral ALA administration is of some value in achieving a clinically meaningful improvement and a slight delay in the progression of neuropathic deficits among patients with mild/moderate diabetic peripheral neuropathy. Despite these promising results, important questions remain to be answered, mainly appropriate patient selection and optimal treatment duration. Moreover, a cost-benefit analysis would be useful.</p>
</abstract>
<kwd-group>
<kwd>alpha-lipoic acid</kwd>
<kwd>diabetes mellitus</kwd>
<kwd>diabetic neuropathy</kwd>
<kwd>oxidative stress</kwd>
<kwd>vascular complications</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Diabetic distal symmetric polyneuropathy (DSPN) develops through 2 major mechanisms, namely chronic glucose toxicity and nerve ischemia.<sup><xref ref-type="bibr" rid="bibr1-0003319711421165">1</xref></sup> The former exerts a neurotoxic effect not only by means of metabolic product accumulation via the polyol pathway but also by lipid peroxidation, nonenzymatic glycosylation, and excessive generation of reactive oxygen species.<sup><xref ref-type="bibr" rid="bibr1-0003319711421165">1</xref></sup> The latter is ascribable to reduced arterial supply to the nerve microvasculature<sup><xref ref-type="bibr" rid="bibr1-0003319711421165">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711421165">2</xref></sup> and may relate to the association between DSPN and vascular risk factors.<sup><xref ref-type="bibr" rid="bibr3-0003319711421165">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319711421165">4</xref></sup> Strict glycemic control represents the foremost therapeutic target in DSPN.<sup><xref ref-type="bibr" rid="bibr5-0003319711421165">5</xref><xref ref-type="bibr" rid="bibr6-0003319711421165"/>–<xref ref-type="bibr" rid="bibr7-0003319711421165">7</xref></sup> Addressing other risk factors, notably hypertension, lipids, and smoking, can also be pursued as part of a multifactorial intervention.<sup><xref ref-type="bibr" rid="bibr8-0003319711421165">8</xref></sup> Nonetheless, a considerably high residual risk of DSPN remains, even when treatment is offered at centers of excellence,<sup><xref ref-type="bibr" rid="bibr9-0003319711421165">9</xref></sup> emphasizing the need for improvement by additional treatment options. So far, add-on disease-modifying agents that have been explored include aldose reductase inhibitors,<sup><xref ref-type="bibr" rid="bibr10-0003319711421165">10</xref></sup> ruboxistaurin,<sup><xref ref-type="bibr" rid="bibr11-0003319711421165">11</xref></sup> cilostazol,<sup>
<xref ref-type="bibr" rid="bibr12-0003319711421165">12</xref></sup> α-lipoic acid (ALA),<sup><xref ref-type="bibr" rid="bibr13-0003319711421165">13</xref>,<xref ref-type="bibr" rid="bibr14-0003319711421165">14</xref></sup> and others with variable results.</p>
<p>α-Lipoic acid, also known as thioctic acid, is a potent lipophilic antioxidant with the ability to scavenge free radicals.<sup><xref ref-type="bibr" rid="bibr15-0003319711421165">15</xref></sup> In experimental models, this antioxidant effect has been clearly shown to reduce lipid peroxidation, improve endoneurial blood flow and glucose uptake, correct deficits in neuropeptides, enhance the activity of endogenous protective superoxide dismutase and catalase, reduce ischemia–reperfusion injury, and prevent apoptosis.<sup><xref ref-type="bibr" rid="bibr15-0003319711421165">15</xref></sup> In humans, ALA has been investigated since 1959 by both small single-blind and larger double-blind randomized placebo-controlled clinical trials.<sup><xref ref-type="bibr" rid="bibr15-0003319711421165">15</xref></sup> α-Lipoic acid has been administered orally at doses between 600 and 1800 mg,<sup>
<xref ref-type="bibr" rid="bibr13-0003319711421165">13</xref>,<xref ref-type="bibr" rid="bibr16-0003319711421165">16</xref>,<xref ref-type="bibr" rid="bibr17-0003319711421165">17</xref></sup> as well as intravenously at 600 mg/d for 3 weeks excluding weekends.<sup><xref ref-type="bibr" rid="bibr14-0003319711421165">14</xref>,<xref ref-type="bibr" rid="bibr18-0003319711421165">18</xref><xref ref-type="bibr" rid="bibr19-0003319711421165"/>–<xref ref-type="bibr" rid="bibr20-0003319711421165">20</xref></sup> The meta-analysis of intravenous investigations<sup><xref ref-type="bibr" rid="bibr14-0003319711421165">14</xref></sup> has shown that ALA is efficacious in ameliorating neuropathic symptoms (pain, burning, and numbness) and neuropathic deficits (ankle reflexes, pinprick, and touch–pressure sensation) with a number needed to treat (NNT) of 6.3 and excellent safety profile. Results with oral ALA have been less consistent, but the most recent and largest trial showed improvement in neuropathic symptoms (especially lancinating and burning pain) and sensory deficits, though not in nerve conduction parameters.<sup><xref ref-type="bibr" rid="bibr13-0003319711421165">13</xref></sup> The trial lasted 5 weeks and the 600 mg dose provided the optimal risk–benefit ratio.<sup><xref ref-type="bibr" rid="bibr13-0003319711421165">13</xref></sup> Based on this latter work, oral ALA appeared promising, but, clearly, more experience and longer follow-up data were necessary.</p>
<p>More recently, the Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial has been published.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup> This is the longest randomized placebo-controlled trial ever conducted in DSPN and included 460 patients with mild/moderate DSPN, who were assigned to 600 mg ALA once daily (n = 233) or matching placebo (n = 227) for 4 years.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup> The primary outcome measure was a composite score based on the Neuropathy Impairment Score of the Lower Limbs plus 7 quantitative sensory and nerve conduction parameters (NIS-LL+7). Secondary end points included clinical signs, as evaluated by the Neuropathy Impairment Score (NIS), the Neuropathy Impairment Score of the Lower Limbs (NIS-LL), and the Neuropathy Symptoms and Change (NSC) score; neuropathic symptoms, as evaluated by the Total Symptom Score (TSS); small fiber function, as evaluated by the cooling detection threshold and the heat pain response slope; and nerve conduction parameters, namely tibial nerve compound muscle action potential and motor nerve conduction velocity, sural sensory nerve action potential latency, and sensory nerve conduction velocity. A clinically meaningful response was defined as a decrease in NIS or NIS-LL by at least 2 points.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref>
</sup> Analysis was based on intention to treat. At baseline, patients did not differ in HbA<sub>1c</sub>. After 4 years, glycemic control was equally improved in both groups, and HbA<sub>1c</sub> again showed no difference. There was a very small difference in the primary outcome measure in favor of ALA, but this was not significant (<italic>P</italic> = .105).<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref>
</sup> Neuropathy Impairment Score improved significantly in ALA-treated patients, whereas it deteriorated in those receiving placebo (<italic>P</italic> = .028). A borderline significant difference was also shown for the muscular weakness subscore of the NIS-LL (<italic>P</italic> = .045) but not for the subscores of sensory function and reflexes. The NSC score for weakness severity also improved on ALA and deteriorated on placebo (<italic>P</italic> = .008). In the ALA group, a clinically meaningful response was more frequently achieved for NIS (<italic>P</italic> = .013) and NIS-LL (<italic>P</italic> = .025), compared with placebo.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup> However, no significant differences between the 2 groups were observed in cold detection threshold and nerve conduction attributes. There was also no significant difference in TSS, but this was expectable, given that only patients with initial TSS &lt; 5, hence almost asymptomatic, were included, so that there was no room for improvement with ALA in this domain. Based on responder rates, the NNTs for improvement in NIS and NIS-LL were 9 and 15, respectively. It was concluded that prolonged ALA treatment led to some improvement in neuropathic signs (mainly muscular weakness) but not in nerve conduction attributes and quantitative sensory testing.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup></p>
<p>In NATHAN 1, ALA was well tolerated. Two patients receiving ALA versus 1 receiving placebo discontinued treatment because of intolerability. Corrected QT prolongation &gt;60 ms was borderline significantly (<italic>P</italic> = .0497) less frequent with ALA than with placebo.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup> Heart rate and rhythm pathology were more common with ALA (<italic>P</italic> = .047), but the individual heart rate, rhythm, myocardial, endocardial, pericardial, and valvular disorders showed no difference between the treatment arms. Furthermore, there were no significant differences in serious adverse events relating to cardiovascular disease, cerebrovascular disorders, infections, and injuries.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup> Deaths were insignificantly (<italic>P</italic> = .294) more frequent in the placebo group. Finally, the global tolerability assessment by patients and investigators alike showed no differences between the groups.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup>
</p>
<p>The strengths of the NATHAN 1 trial include the relatively large number of patients, longer follow-up, comprehensive neuropathy assessment by experienced personnel, and robust analysis. The failure to demonstrate superiority in the primary end point may be considered a limitation of the study. Nonetheless, it may also be seen as a further strength, inasmuch as this trial reflects the current real-world situation, in which optimized glycemic control is feasible and should be utilized to halt the progression of DSPN. Based on improved metabolic control and current standard treatment, a modest benefit may nowadays be even accomplished with placebo.<sup><xref ref-type="bibr" rid="bibr22-0003319711421165">22</xref></sup> Indeed, the ability of ALA to confer some improvement, in addition to and independently of improved glycemic control as pursued in both treatment arms, favors its potential value as a therapeutic adjunct in DSPN.</p>
<p>The practical implication of the present study is that prolonged oral ALA administration in patients with mild/moderate DSPN is tolerable and may lead to a clinically meaningful improvement along with reduced progression in neuropathic deficits.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref>
</sup> This improvement notwithstanding, a number of issues urgently await clarification. The first relates to the preferential action in neuropathic deficits but not in nerve conduction parameters or quantitative sensory testing. Of note, a similar therapeutic disparity was seen in the shorter 5-week oral ALA trial.<sup><xref ref-type="bibr" rid="bibr13-0003319711421165">13</xref></sup> Arguably, as the authors themselves suggested, the improvement in neuropathic deficits may be directly attributable to the ALA-induced increase in nerve blood flow, whereas other, as yet poorly defined, mechanisms may underlie the remaining neuropathic attributes. Second, we need a cost–benefit analysis, if we are to encourage ALA prescription.<sup><xref ref-type="bibr" rid="bibr23-0003319711421165">23</xref></sup> Moreover, it would be extremely useful to know whether ALA might prove efficacious in any patient with mild/moderate DSPN or whether appropriate a priori selection of those patients who are more likely to respond should be achieved by some means. Interestingly, certain disease characteristics have been identified as predictors of response to duloxetine in the treatment of painful DSPN,<sup><xref ref-type="bibr" rid="bibr24-0003319711421165">24</xref></sup> and the same would be most welcome for ALA. Finally, further clarification of the optimal treatment duration is desirable.</p>
<p>In conclusion, the NATHAN 1 trial has demonstrated that prolonged oral ALA administration is of some value in achieving a clinically meaningful improvement and a slight delay in the progression of neuropathic deficits among patients with mild/moderate DSPN.<sup><xref ref-type="bibr" rid="bibr21-0003319711421165">21</xref></sup> Although important questions remain to be answered, this therapeutic prophecy merits further consideration for direct application to clinical practice.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711421165">
<p>The authors declared a potential conflict of interest: This Editorial was written independently. Dr N Papanas has been an advisory board member of TrigoCare International, has participated in sponsored studies by Novo Nordisk and Novartis, has received honoraria as a speaker for Novo Nordisk and Pfizer, and attended conferences sponsored by TrigoCare International, Novo Nordisk, Sanofi-Aventis, and Pfizer. Professor E Maltezos has participated in sponsored studies by Novo Nordisk and Novartis and attended conferences sponsored by Wyeth, Pfizer, and Bayer.</p></fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711421165"><p>The authors received no financial support for the research, authorship, and/or publication of this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711421165">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murakawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sima</surname>
<given-names>AA.</given-names>
</name>
</person-group> <article-title>Diabetic neuropathy—a continuing enigma</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2000</year>;<volume>16</volume>(<issue>6</issue>):<fpage>408</fpage>–<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711421165">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesfaye</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis)</article-title>. <source>Diabetologia</source>. <year>1996</year>;<volume>39</volume>(<issue>3</issue>):<fpage>329</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711421165">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesfaye</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chaturvedi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>SE</given-names>
</name>
<etal/>
</person-group>. <article-title>Vascular risk factors and diabetic neuropathy</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>4</issue>):<fpage>341</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711421165">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rathmann</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dickhaus</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Meisinger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mielck</surname>
<given-names>A.</given-names>
</name>
</person-group> and <collab collab-type="author">the KORA Study Group</collab>. <article-title>Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3</article-title>. <source>Diabetes Care</source>. <year>2008</year>;<volume>31</volume>(<issue>3</issue>):<fpage>464</fpage>–<lpage>469</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711421165">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albers</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Pop-Busui</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>(<issue>5</issue>):<fpage>1090</fpage>–<lpage>1096</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711421165">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ismail-Beigi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Craven</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Banerji</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>(<issue>9739</issue>):<fpage>419</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711421165">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Roden</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Near-normoglycaemia prevents the development of polyneuropathy. A 24-year prospective study from the diagnosis of type 1 diabetes</article-title>. <source>Diabetologia</source>. <year>2010</year>;<volume>53</volume>(<issue>suppl 1</issue>):<fpage>S16</fpage> (<lpage>A25</lpage>).</citation>
</ref>
<ref id="bibr8-0003319711421165">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaede</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vedel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Parving</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>O.</given-names>
</name>
</person-group> <article-title>Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>348</volume>(<issue>5</issue>):<fpage>383</fpage>–<lpage>393</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711421165">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fioretto</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dodson</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rosenson</surname>
<given-names>RS.</given-names>
</name>
</person-group> <article-title>Residual microvascular risk in diabetes: unmet needs and future directions</article-title>. <source>Nat Rev Endocrinol</source>. <year>2010</year>;<volume>6</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711421165">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bril</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>RA.</given-names>
</name>
</person-group> <article-title>Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>(<issue>1</issue>):<fpage>68</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711421165">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casellini</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Barlow</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>AL</given-names>
</name>
<etal/>
</person-group>. <article-title>A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy</article-title>. <source>Diabetes Care</source>. <year>2007</year>;<volume>30</volume>(<issue>4</issue>):<fpage>896</fpage>–<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711421165">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E.</given-names>
</name>
</person-group> <article-title>Cilostazol in diabetic neuropathy: premature farewell or new beginning?</article-title> <source>Angiology</source>. <comment>[published online ahead of print April 20, 2011].</comment>
</citation>
</ref>
<ref id="bibr13-0003319711421165">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ametov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barinov</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>(<issue>11</issue>):<fpage>2365</fpage>–<lpage>2370</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711421165">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kempler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vargha</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>PA.</given-names>
</name>
</person-group> <article-title>Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysis</article-title>. <source>Diabet Med</source>. <year>2004</year>;<volume>21</volume>(<issue>2</issue>):<fpage>114</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711421165">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D.</given-names>
</name>
</person-group> <article-title>Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review</article-title>. <source>Treat Endocrinol</source>. <year>2004</year>;<volume>3</volume>(<issue>3</issue>):<fpage>173</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711421165">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruhnau</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Meissner</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy</article-title>. <source>Diabet Med</source>. <year>1999</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1040</fpage>–<lpage>1043</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711421165">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reljanovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reichel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rett</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy</article-title>. <source>Free Radic Res</source>. <year>1999</year>;<volume>31</volume>(<issue>3</issue>):<fpage>171</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711421165">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hanefeld</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruhnau</surname>
<given-names>KJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)</article-title>. <source>Diabetologia</source>. <year>1995</year>;<volume>38</volume>(<issue>12</issue>):<fpage>1425</fpage>–<lpage>1433</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711421165">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hanefeld</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruhnau</surname>
<given-names>KJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy</article-title>. <source>Diabetes Care</source>. <year>1999</year>;<volume>22</volume>(<issue>8</issue>):<fpage>1296</fpage>–<lpage>1301</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711421165">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ametov</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Barinov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dyck</surname>
<given-names>PJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>(<issue>3</issue>):<fpage>770</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711421165">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Litchy</surname>
<given-names>WJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy and safety of antioxidant treatment with {alpha}-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial</article-title>. <source>Diabetes Care</source>. <comment>[published online ahead of print July 25, 2011].</comment>
</citation>
</ref>
<ref id="bibr22-0003319711421165">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesfaye</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tandan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bastyr</surname>
<given-names>EJ 3rd</given-names>
</name>
<etal/>
</person-group>. <article-title>Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials</article-title>. <source>Diabetes Care</source>. <year>2007</year>;<volume>30</volume>(<issue>10</issue>):<fpage>2626</fpage>–<lpage>2632</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711421165">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathmann</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Haastert</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Delling</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gries</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Giani</surname>
<given-names>G.</given-names>
</name>
</person-group> <article-title>Postmarketing surveillance of adverse drug reactions: a correlational study approach using multiple data sources</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>1998</year>;<volume>7</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711421165">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pritchett</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain</article-title>. <source>Diabetes Care</source>. <year>2007</year>;<volume>30</volume>(<issue>3</issue>):<fpage>664</fpage>–<lpage>669</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>